-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
1-2-1 Meetings / Networking Break
-
Allogeneic
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
Evening Drinks Reception
-
iPSCs Technology
Clinical grade iPSC line generation: which method is the ideal one ? As fully differentiated cells a
...
-
Autologous
Developing robust processes in early phase with commercial already in mind Removing roadblocks to sc
...
-
Autologous
The device used to manufacture an immunotherapeutic agent is a highly relevant factor in ensuring th
...
-
Allogeneic
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
1-2-1 Meetings / Networking Break
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
Afternoon Refreshments
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
Networking Lunch
-
Measuring Product Potency
-
Measuring Product Potency
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
Registration
-
iPSCs Technology
What are the manufacturing implications of the recent FDA guidelines from January 2024 on “Human Gen
...
-
Allogeneic
What is the current terminal scale of allogeneic CGT production with respect to total cell numbers a
...
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
1-2-1 Meetings / Networking Break
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
Morning Refreshments
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
1-2-1 Meetings/Networking Break
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
1-2-1 Meetings/Networking Break
-
Allogeneic
-
Measuring Product Potency
-
Measuring Product Potency
-
iPSCs Technology
-
-
Allogeneic
-
Autologous
-
iPSCs Technology
-
Measuring Product Potency
)
The device used to manufacture an immunotherapeutic agent is a highly relevant factor in ensuring th ...)
)
![Sponsor Led Roundtable: De-risking programs and improving timelines when transitioning from pre-clinical to first in human and ultimately, commercial production [Allogeneic Topic]](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/WuXi-Advanced-Therapies.png/fit-in/500x9999/filters:no_upscale())
)
What are the manufacturing implications of the recent FDA guidelines from January 2024 on “Human Gen ...)
What is the current terminal scale of allogeneic CGT production with respect to total cell numbers a ...)
)
)
)
)
)
)
)
)
)
)
)